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Objective: We investigated the clinical characteristics and follow-up results of pa-
tients with a lower urinary tract inverted papilloma (IP) in our hospital, with the in-
tention of clarifying whether certain groups require more aggressive surveillance.
Materials and Methods: We conducted a retrospective study of lower urinary tract 
IP, using the pathology database of Taipei Veterans General Hospital, from 
September 1992 to February 2008. In total, 67 patients were enrolled. Patients’ clin-
ical characteristics, symptoms, tumor locations, and follow-up data were analyzed.
Results: Among the 67 patients diagnosed with IP, 59 were male and eight were 
female, with a mean age of 67.9 ± 12.4 years. Gross hematuria and lower-urinary-tract 
symptoms were the most common symptoms. All of the patients received transure-
thral resection as initial treatment. Thirty-eight of these patients were monitored 
for a median of 21 months (range: 3–168 months). Seven patients had synchronous 
urothelial malignancies, and one had recurrent IP during follow-up. No patient had 
subsequent urothelial carcinoma or IP recurrence without a synchronous or previous 
urothelial malignancy during follow-up.
Conclusion: There is a low incidence of developing a subsequent malignancy with a 
simple IP lesion during follow-up. Rigorous surveillance may be unnecessary in IP 
patients without a synchronous or previous urothelial malignancy.
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1.  Introduction
An inverted papilloma (IP) is an uncommon urinary tract 
lesion that accounts for approximately 2% of all urothe-
lial neoplasms.1 It was first described by Potts and Hirst 
in 1963, and is characterized by a trabeculated pattern 
of proliferating urothelium that is arranged in inverted 
cords and nests.2 Although an IP is usually regarded as a 
benign lesion based on histological findings, it some-
times causes obstruction in the upper urinary tract, and 
is found with a urothelial malignancy in some cases.3–6 
Therefore, the question of whether IP is a benign neo-
plasm or a precursor of malignancy remains, and the 
necessity of aggressive surveillance is also currently 
being debated.
At our hospital, we recommend that patients diag-
nosed with lower urinary tract IP (bladder and prostatic 
urethra) have regular cystoscopic monitoring. The aim 
of this study was to investigate the clinical characteris-
tics and follow-up results of IP patients treated at our 
hospital, with the intention of clarifying whether certain 
groups require more aggressive surveillance.
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2.  Materials and Methods
From September 1992 to February 2008, we retrospec-
tively identified 78 patients who were diagnosed with 
urinary tract IP lesions at Taipei Veterans General Hospi-
tal, and 67 patients were enrolled in this study. Among 
the patients, 38 had follow-up data after transurethral 
resection of IP. Patient characteristics (sex, age, initial 
symptoms, previous urinary tract malignancy, and initial 
diagnostic tool), tumor characteristics (multiplicity, site, 
and association with malignancy), and follow-up results 
were retrospectively analyzed. All histological slides 
were reviewed by uropathologists, and surveillance was 
performed using rigid cystoscopy approximately every 
3 months. The follow-up period was defined as the time 
from diagnosis to the final cystoscopic examination.
3.  Results
Sixty-seven patients were recruited for the study: 59 men 
and eight women, with a mean age at presentation of 
67.9 ± 12.4 years (range: 26–86 years). Nine (14%) of these 
patients had a history of previous urinary tract malig-
nancy. Most patients presented with lower-urinary-tract 
symptoms or gross hematuria as the initial symptom 
(Table 1). Other patients had findings incidental to routine 
health examinations and previous genitourinary tract 
malignancies. The initial diagnostic tools for IP were cys-
toscopy and sonography in most patients. Other charac-
teristics are listed in Table 1.
3.1.  IP location
The locations of the lower urinary tract IP lesions are 
listed in Table 2. After transurethral resection of the 
bladder tumor, more than half (58%) of the IP lesions 
were located in the trigone and bladder neck.
3.2.  Operative and follow-up results
Of the 67 lower urinary tract IP patients, eight (12%) had 
a synchronous malignancy: six with bladder cancer and 
two with renal pelvis cancer. Four patients (6%) had 
multifocal IP (2–4 tumors). Among these, two patients 
had IP combined with a synchronous renal pelvis urothe-
lial carcinoma that was found at the time of surgery for 
IP; both patients underwent a nephroureterectomy and 
bladder cuff excision. One of the patients with invasive 
renal pelvis cancer died of the disease.
Follow-up data were available for 38 patients, and the 
median follow-up duration was 21 months (range: 3–168 
months). These patients were divided into two groups 
according to their previous malignancy histories (Figure 1). 
In the group with a history of previous malignancy, one 
(12%) had a synchronous malignancy and recurrent pT1 
bladder urothelial carcinoma 6 months after surgery. 
Table 1  Patient and tumor characteristics in 67 patients 
with a lower-urinary-tract inverted papillomaa
Characteristic n (%)
Sex 
 Male 59 (88)
 Female 8 (12)
Age (yr) 67.9 ± 12.4 (26–86)
Previous urothelial malignancy history 9 (13)
Symptoms
 LUTS (e.g. dysuria, voiding difficulty) 28 (41)
 Gross hematuria 17 (26)
 Incidental finding during another  9 (14)
  operation (e.g. TURP)
 During follow-up of a previous  7 (10)
  urothelial malignancy
 Microhematuria 6 (9)
Initial diagnostic tools
 Cystoscopy 42 (63)
 Sonography 15 (22)
 Intravenous pyelography 6 (9)
 Computed tomography 3 (4.5)
 Magnetic resonance imaging 1 (1.5)
aData are presented as n (%) or mean ± standard deviation (range). 
LUTS = lower-urinary-tract symptoms; TURP = transurethral resec-
tion of the prostate.
Table 2  Tumor locations in 67 patients with a lower-urinary-
tract inverted papilloma
Location n (%)
Bladder
 Trigone 21 (31.2)
 Bladder neck 18 (26.8)
 Left lateral wall 6 (9.0)
 Anterior wall 6 (9.0)
 Right lateral wall 4 (6.0)
 Posterior wall 4 (6.0)
 Dome 2 (3.0)
 Prostatic urethra 3 (4.5)
 Not available 3 (4.5)
Another patient without a synchronous malignancy had 
IP recurrence 20 months after IP tumor removal. Of the 
six patients with a previous history of superficial cancer, 
one developed recurrent superficial bladder cancer 6 
months after surgery and an invasive tumor 3 years 
later, and eventually died of the disease. The remaining 
five patients were free of disease during follow-up.
Of the 30 patients who had no history of urothelial 
malignancy, six (20%) had a synchronous urothelial ma-
lignancy that was found during surgery for IP. One of the 
six patients had invasive bladder cancer and succumbed 
to the disease soon after diagnosis. All of the remaining 
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24 patients with no history of malignancy after IP sur-
gery were disease-free during the follow-up period.
When looking for patients without a synchronous ma-
lignancy at diagnosis of bladder tumor, only one patient 
with a previous history of bladder cancer developed re-
current IP 20 months later. He remained disease-free for 
2 years after his second transurethral resection to the 
time of his last follow-up. All four patients with multiple 
IP tumors were disease-free during follow-up (follow-up 
time: 11–69 months) except for one who soon died of 
invasive renal pelvis cancer.
4.  Discussion
A brief review of IP studies is given in Table 3, with > 500 
cases in the past two decades.1,7–16 The largest study was 
done by Wan et al., and included 151 patients over the 
course of 12 years. They reported an incidence of 4.9% of 
IP among all bladder tumors.10 Most IP tumors were found 
in patients aged 50–70 years. In our study, the mean age 
of IP patients was 67.9 years, which is consistent with 
other studies.1,7–16 Juvenile IP has also been reported, 
with a clinical course similar to that in aged patients.17 
Our study also showed a predilection for males among our 
IP patients, with a ratio of men to women of 7.38: 1. In 
previous studies, the ratio was 6–10: 1.1,7–16 Additionally, 
previous studies have indicated that the etiology of IP is 
associated with chronic inflammation, smoking, and other 
chemical agents.10 Chan et al. have reported the pres-
ence of human papillomavirus type 18 in six of 10 IP pa-
tients, which suggests an oncogenic role in IP lesions.18 
Clarification of risk factors for IP still require studies with 
larger patient populations.
The most common symptoms of IP are lower-urinary-
tract symptoms and gross hematuria, which also occurred 
among our patients (66%). Among our patients, 24% of 
the IP tumors were incidentally found on sonography or 
during endoscopic surgery such as transurethral resec-
tion of the prostate or ureteroscopy. Cystoscopy remains 
the most sensitive diagnostic tool and can help localize 
tumors. Imaging studies such as intravenous pyelography 
and computed tomography can be used for screening of 
the upper urinary tract for IP or other synchronous lesions. 
We did not submit urine cytology data because some of 
our patients had a history of previous malignancy. Typi-
cally, IP patients have negative urine cytology results be-
cause of its histological characteristics. Ho et al. have 
reported a 94% negative rate among 52 patients.9 In a 
study by Witjes et al., 14% of patients had only mild atypia 
Table 3  Urinary tract inverted papilloma follow-up results in recent studies (with > 30 patients)
Reference Year
 No. of Follow-up  Previous UC Synchronous Recurrence Subsequent 
  patients patient no. history malignancy of IP malignancya
Witjes et al.14 1997  37  31 0 0 2 1
Cheville et al.13 2000  51  51 1 6 0 1
Asano et al.12 2003  48  42 1 5 1 2
Wan et al.10 2005 151 118 NA NA 5 2
Ho et al.9 2006  52  52 0 0 0 1
Sung et al.8 2006  75  75 0 0 1 0
Seung et al.16 2010  53  53 3 1 0 0
Current study   67  38 8 7 1 0
 aPatients with no previous malignancy history. UC = urothelial carcinoma; IP = inverted papilloma; NA = not available.
Figure 1 Follow-up results in 38 patients with lower-urinary-tract inverted papilloma. UC = urothelial carcinoma; OP = operation.
Follow-up 38 paents
30 pts without UC history
6 pts with synchronous UC
24 pts without synchronous UC
No recurrence
1 recurrent pT2 UC, 2 months
aer OP (invasive UC, pT2)
7 pts without synchronous UC
1 recurrent IP 20 months aer OP
1 recurrent pT1 UC, 6 months aer OP
1 pt with synchronous
UC, pTa (previous pTa)
8 pts with previous UC history
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of the urothelium.14 Therefore, cytology is of limited use 
among IP patients.
On cystoscopic imaging, IP presents as a smooth-
surfaced, non-papillary lesion with a pedunculated or 
sessile appearance. Occasionally, IP is difficult to differ-
entiate from other lesions, such as cystitis cystica, cystitis 
glandularis, and urothelial malignancies. The majority of 
IP lesions are found in the lower urinary tract, with an 
incidence of 80–95%.1,7–16 In our study, we enrolled only 
patients with bladder and prostatic urethral IP, because of 
the ease of cystoscopic follow-up. Among our IP patients, 
the most common locations for IP were the trigone (31%) 
and bladder neck (27%), which are similar to those in 
other IP studies (50–80%).1,7–16 Transurethral resection 
remains the standard treatment for IP lesions of the 
lower urinary tract.
In our study, most of the IP lesions occurred singly, 
but multiple lesions were found in four patients (6%). 
Our data are consistent with a study by Cheng et al., 
who have reported an incidence of multiplicity of 4.4% 
in a review of 322 patients with lower urinary tract IP.11 
Another review of 277 patients by Witjes et al. has re-
ported an incidence of IP multiplicity of 5.4%.14 In con-
trast, the chances of developing multiple IP tumors is 
much lower than that for urothelial carcinoma, which 
has a 35% rate of multiplicity.19 Simultaneous presenta-
tion of a urothelial malignancy and IP has also been re-
ported in previous studies.1,7–16 In addition, eight patients 
(12%) had synchronous malignancies, and most of them 
had no previous history of urothelial malignancy. In a 
study by Asano et al., five of 48 patients (10%) had syn-
chronous malignancies.12 Larger studies have reported 
rates of simultaneous urothelial carcinoma and IP of 
5.9–12%.11–13 Importantly, half of the multiple IP patients 
in our study had a synchronous urothelial malignancy, 
which is much greater than the rate among patients with 
single IP lesions. We recommend that when multiple IP 
lesions are found, care should be taken to look for an ac-
companying synchronous malignancy.
Overall, we found that the characteristics of IP were 
benign owing to its low recurrence rate during follow-up. 
Only one of 38 patients developed recurrence of IP after 
20 months of follow-up. That patient had a history of 
bladder cancer and was disease-free after a second trans-
urethral resection of the bladder tumor. Twenty-four 
patients with no urothelial malignancy history or synchro-
nous malignancy were disease-free during our follow-up. 
Sung et al. have reported that only one of 75 patients 
without a synchronous or previous urothelial malignancy 
developed recurrent IP, and no patient had a subsequent 
urothelial malignancy during follow-up.8 Cheng et al. have 
reviewed 260 patients with lower-urinary-tract IP and 
have calculated a rate of subsequent urothelial malig-
nancy of 2.7%.11 Moreover, if those patients had no pre-
vious urothelial malignancy or synchronous malignancy, 
the incidence of subsequent urothelial malignancy was 
only 1.5%, which was significantly lower.11
Histologically, IP is a benign neoplasm with trabecu-
lations of the urothelium and has an endophytic growth 
pattern. Henderson et al. have defined several criteria 
for diagnosis of IP lesions, including an inverted configu-
ration, a covering layer of urothelium, uniformity of epi-
thelial cells, absence or rarity of mitoses, formation of 
microcysts (crypts), and squamous metaplasia.20 How-
ever, few cases of concurrent urothelial malignancy in-
side IP lesions or a urothelial carcinoma with an inverted 
growth pattern have been reported.21 Additionally, IP le-
sions in the bladder could have focal papillary patterns.22 
The accuracy of the histopathological diagnosis is very 
important if IP lesions have atypical features or resemble 
a low-grade urothelial carcinoma. In a study by Witjes 
et al., the misdiagnosis rate was 27% after reviewing his-
tological slides for which most of the misdiagnoses were 
actually low-grade urothelial malignancies.14 The accuracy 
of the results also influences patient treatment plans and 
surveillance. Several immunohistochemical stains can help 
to distinguish between these lesions. Cytokeratin 20, p53, 
and Ki67 are the most common immunohistochemical 
markers that are increased in urothelial carcinoma.23–25 
Broussard et al. have evaluated 11 atypical IP cases using 
these immunohistochemical stains.26 They have found no 
significant increases in these markers in IP lesions, which 
indicates no association between IP and urothelial carci-
noma based on the markers. To predict further malignant 
changes, Urakami et al. have reported that when IP lesions 
have high immunoreactivity for proliferating cell nuclear 
antigen, p53, and intense Feulgen staining, the lesions are 
more susceptible to malignant transformation, because 
of the high proliferative activity.27
With the advancement of molecular analyses, Lott 
et al. have reported that among 78 IP lesions, none de-
veloped mutations of the tumor suppression gene, Tp53, 
which supports the concept that IP lesions differ from 
urothelial malignancies.28 Sung et al. also have analyzed 
IP lesions with several polymorphic microsatellite DNA 
markers in which alterations frequently occur in urothelial 
carcinoma.29 They have reported that the incidence of 
loss of heterozygosity in these markers is low, which dif-
fers from urothelial carcinoma. In a study by Eiber et al., 
which has combined histopathological and molecular 
analyses, IP lesions lacked specific genetic alterations, 
and the rate of aberrant immunostaining was low com-
pared to that of urothelial carcinoma with a prominent 
inverted growth pattern.30 These studies have strongly 
supported our hypothesis that IP is more likely a benign 
lesion rather than a malignancy. Furthermore, Jones et al. 
have used fluorescence in situ hybridization, immuno-
histochemistry, and morphological analysis to differenti-
ate inverted urothelial carcinomas and IP lesions.21 All of 
the IP lesions had normal results compared to a 72% pos-
itive rate for urothelial carcinomas with an inverted growth 
pattern. The UroVysion fluorescence in situ hybridization 
test was useful in distinguishing between these lesions. 
It provided further evidence that IPs and urothelial 
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carcinomas are phenotypically and genotypically dis-
tinct neoplasms.
Although we believe that IP is a benign neoplasm, sev-
eral strengths and limitations of this study deserve com-
ment. First, this was a retrospective study, and some of 
our patients were lost to follow-up. We usually performed 
rigid cystoscopy; therefore, some patients may have been 
afraid of the discomfort associated with the examina-
tion and thus been unwilling to participate in follow-up. 
Second, patients with multiple IPs were extremely rare; 
therefore, we could not determine whether these pa-
tients were prone to a concurrent urothelial malignancy. 
A study with a larger patient population should be car-
ried out to validate our findings. Third, we did not have 
direct evidence to prove that subsequent bladder cancer 
had no correlation with previous IP lesions. Further his-
topathological research is needed.
We suggest that patients with IP receive regular sur-
veillance. For a patient with a simple IP lesion, previous 
studies have suggested a 3-month or biannual cystoscopic 
examination,11,12 but recent studies have recommended 
less rigorous surveillance because of its benign charac-
teristics.8,9 A 6-month or longer period between cysto-
scopic examinations may be sufficient.
In summary, IP is a benign lesion rather than a precur-
sor of malignancy. Our study demonstrated that patients 
with a simple IP lesion had a low incidence rate of devel-
oping a subsequent malignancy. Rigorous preventive in-
terventions may be unnecessary in IP patients without a 
synchronous or previous urothelial neoplasm.
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